Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis
Zabalza, Ana (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Arrambide, Georgina (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Tagliani, Paula (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Cárdenas-Robledo, Simón (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Otero-Romero, Susana (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Esperalba, Juliana (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Fernandez-Naval, Candela (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Trocoli Campuzano, Jesus (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Martínez Gallo, Mónica (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Castillo, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Bonastre, Mercè (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Resina Sallés, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Beltran, Jordina (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Carbonell-Mirabent, Pere (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Rodríguez-Barranco, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca)
López-Maza, Samuel (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Melgarejo Otálora, Pedro José (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Ruiz-Ortiz, Mariano (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Pappolla, Agustin (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Rodríguez Acevedo, Breogán (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Midaglia, Luciana (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Vidal-Jordana, Angela (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Cobo-Calvo, Álvaro (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Tur, Carmen (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Galan, Ingrid (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Castilló, Joaquín (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Río, Jordi (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Espejo, Carmen (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Comabella, Manuel (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Nos, Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Sastre-Garriga, Jaume (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Tintoré, Mar (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Montalban, Xavier (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Information about humoral and cellular responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and antibody persistence in convalescent (COVID-19) patients with multiple sclerosis (PwMS) is scarce. The objectives of this study were to investigate factors influencing humoral and cellular responses to SARS-CoV-2 and its persistence in convalescent COVID-19 PwMS. This is a retrospective study of confirmed COVID-19 convalescent PwMS identified between February 2020 and May 2021 by SARS-CoV-2 antibody testing. We examined relationships between demographics, MS characteristics, disease-modifying therapy (DMT), and humoral (immunoglobulin G against spike and nucleocapsid proteins) and cellular (interferon-gamma [IFN-γ]) responses to SARS-CoV-2. A total of 121 (83. 45%) of 145 PwMS were seropositive, and 25/42 (59. 5%) presented a cellular response up to 13. 1 months after COVID-19. Anti-CD20-treated patients had lower antibody titers than those under other DMTs (p < 0. 001), but severe COVID-19 and a longer time from last infusion increased the likelihood of producing a humoral response. IFN-γ levels did not differ among DMT. Five of 7 (71. 4%) anti--CD20-treated seronegative patients had a cellular response. The humoral response persisted for more than 6 months in 41/56(81. 13%) PwMS. In multivariate analysis, seropositivity decreased due to anti-CD20 therapy (OR 0. 08 [95% CI 0. 01-0. 55]) and increased in males (OR 3. 59 [1. 02-12. 68]), whereas the cellular response decreased in those with progressive disease (OR 0. 04 [0. 001-0. 88]). No factors were associated with antibody persistence. Humoral and cellular responses to SARS-CoV-2 are present in COVID-19 convalescent PwMS up to 13. 10 months after COVID-19. The humoral response decreases under anti-CD20 treatment, although the cellular response can be detected in anti-CD20-treated patients, even in the absence of antibodies.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Neurology® neuroimmunology & neuroinflammation, Vol. 9 (february 2022) , ISSN 2332-7812

DOI: 10.1212/NXI.0000000000001143
PMID: 35105687

13 p, 780.6 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats